Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.99% | 194.78 | 1.3% | $536.34m | |
| GILD | Gilead Sciences, Inc. | -0.24% | 66.01 | 0.9% | $359.16m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -4.85% | 102.60 | 2.0% | $309.75m | |
| ILMN | Illumina, Inc. | 1.31% | 302.18 | 3.5% | $307.20m | |
| BIIB | Biogen Inc. | -1.25% | 235.72 | 1.3% | $295.96m | |
| CELG | Celgene Corporation | 0.14% | 98.74 | 1.3% | $288.77m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.29% | 82.94 | 14.6% | $174.77m | |
| A | Agilent Technologies, Inc. | 0.52% | 76.80 | 1.6% | $174.25m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.76% | 174.66 | 1.9% | $173.21m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.00% | 282.37 | 2.6% | $169.16m | |
| EXAS | Exact Sciences Corporation | -1.74% | 105.01 | 24.1% | $132.84m | |
| ACAD | ACADIA Pharmaceuticals Inc. | -3.76% | 41.00 | 13.9% | $110.65m | |
| INCY | Incyte Corporation | -1.33% | 78.05 | 2.5% | $84.58m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.67% | 75.50 | 4.3% | $71.70m | |
| ALDR | Alder Biopharmaceuticals, Inc. | 0.54% | 18.80 | 10.2% | $64.28m |
Company Profile
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.